pyrroles has been researched along with avasimibe in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alegret, M; Díaz, C; Hernández, G; Jové, M; Laguna, JC; Llaverías, G; Sánchez, RM; Vázquez-Carrera, M | 1 |
| Heinonen, T; Klepack, E; Lovalvo, J; Marais, AD; McLain, R; Raal, FJ | 1 |
| Badimon, JJ; Chew, DP; Corti, R; Fallon, JT; Fayad, ZA; Fuster, V; Helft, G; Worthley, MI; Worthley, SG; Zaman, AG | 1 |
1 trial(s) available for pyrroles and avasimibe
| Article | Year |
|---|---|
Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
Topics: Acetamides; Acetates; Administration, Oral; Adolescent; Adult; Age Factors; Atorvastatin; Child; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Sex Factors; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sulfonamides; Sulfonic Acids; Treatment Outcome | 2003 |
2 other study(ies) available for pyrroles and avasimibe
| Article | Year |
|---|---|
Avasimibe and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages.
Topics: Acetamides; Acetates; Atorvastatin; Cells, Cultured; Cholesterol Esters; Drug Synergism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Pyrroles; Sulfonamides; Sulfonic Acids | 2002 |
Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Topics: Acetamides; Acetates; Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Catheterization; Cholesterol; Disease Progression; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Magnetic Resonance Imaging; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Pyrroles; Rabbits; Random Allocation; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2007 |